Zhou et al. reported that isorhamnetin alleviated liver fibrosis by inhibiting extracellular matrix formation via TGF-β1/p38 MAPK pathway (Liu et al., 2019). The gene discussed is TGFB1; the disease is Hepatic fibrosis.